Myelofibrosis
Myelofibrosis
Advertisement
Melissa BadamoMyelofibrosis | February 13, 2024
The study evaluated the impact of mutations on the risk of thromboembolic events, disease progression, and patient mortality.
Read More
Patrick DalyMyelofibrosis | February 13, 2024
Fedratinib induced superior spleen volume and symptom response versus best available therapy in patients with myelofibrosis.
Patrick DalyMyelofibrosis | February 16, 2024
Dr. Hobbs shared findings supporting the safety and feasibility of continuing ruxolitinib during and after HSCT for MF.
Heme Today Staff WritersMyelofibrosis | January 17, 2024
A pooled study showed treatment with ruxolitinib achieved durable hematocrit control.
Lucia Masarova, MDHematology | February 16, 2024
Dr. Lucia Masarova described data from SIMPLIFY-1 on medical costs and time burden related to outpatient transfusion in MF.
Patrick DalyMyelofibrosis | February 13, 2024
Ruxolitinib plus navitoclax induced 24-week spleen volume reduction rates twice as high as ruxolitinib plus placebo in MF.
Patrick DalyMyelofibrosis | February 13, 2024
Pelabresib plus ruxolitinib induced significant spleen volume reduction rates without limiting toxicities in myelofibrosis.
Patrick DalyHematology | February 16, 2024
Dr. Masarova spoke with HemeToday on findings from a treatment comparison of pacritinib and momelotinib in myelofibrosis.
Rob DillardASCO 2023 | September 26, 2023
Treatment using a BET inhibitor as a monotherapy and in combination with appears well-tolerated in myelofibrosis.
Dr. Ruben MesaASCO 2023 | September 26, 2023
Ruben Mesa, MD, spoke at ASCO 2023 about the affect myelofibrosis has on patients’ quality of life.
Rob DillardASCO 2023 | September 26, 2023
Zilurgisertib appears safe and well tolerated in patients who have anemia due to myelofibrosis.
Rob DillardASCO 2023 | September 26, 2023
A proof-of-concept study indicates the combined use of ruxolitinib and magrolimab is effective in treating myelofibrosis.
Rob DillardASCO 2023 | September 26, 2023
The treatment combination of selinexor plus ruxolitinib is effective in treatment-naïve patients with myelofibrosis.
Rob DillardASCO 2023 | September 26, 2023
The JAK inhibitor momelotinib appears to have a superior safety profile compared with fedratinib in myelofibrosis.
Rob DillardASCO 2023 | September 26, 2023
Patients with myelofibrosis with a certain platelet count who achieve spleen volume reduction on pacritinib have better OS.
Rob DillardASCO 2023 | September 26, 2023
The novel JAK1-sparing inhibitor pacritinib is effective at reducing spleen enlargement and disease burden in MF patients.
Rob DillardASCO 2023 | September 26, 2023
The safety and efficacy of luspatercept is favorable for treating anemia in patients with myelofibrosis.
Patrick DalyASH Annual Meeting 2022 | September 26, 2023
According to Harinder Gill, MD, MBBS, FRCP, FRCPath, there is no optimal treatment strategy established for patients ...
Patrick DalyASH Annual Meeting 2022 | September 26, 2023
In the phase 2 MANIFEST trial, John Mascarenhas, MD, and colleagues evaluated pelabresib, an oral bromodomain and ...
Patrick DalyASH Annual Meeting 2022 | September 26, 2023
Studies have shown the JAK2 V617F somatic driver mutation is associated with disease progression in patients with ...
Advertisement
Advertisement
Advertisement
Latest News

February 23, 2024